financetom
Market
financetom
/
Market
/
Adar Poonawalla at IBLA: Serum, Biocon aim to leverage the ability to make monoclonal antibodies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Adar Poonawalla at IBLA: Serum, Biocon aim to leverage the ability to make monoclonal antibodies
Apr 4, 2022 5:06 AM

Speaking from the sidelines of CNBC-TV18 India Business Leader Awards 2022, Adar Poonawalla, CEO of Serum Institute of India said partnership with Biocon not limited to COVID vaccines. He said Serum, Biocon aim to leverage the ability to make monoclonal antibodies as well.

Wockhardt tie-up is limited to manufacture of vaccines in UK, he said.

Poonawalla was named Business Leader of the Year at IBLA 2022 held on April 1.

Watch video for more.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved